1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Prurigo Nodularis Market Overview at a Glance

6.1. Market Share (%) Distribution of Prurigo Nodularis by Therapies in 2023

6.2. Market Share (%) Distribution of Prurigo Nodularis by Therapies in 2032

7. Disease Background and Overview

7.1. Introduction

7.2. Classification

7.3. Clinical Signs and Symptoms

7.4. Pathophysiology

7.5. Diagnosis

7.6. Differential Diagnosis

7.7. Etiology

7.8. Treatment and Management

7.8.1. Treatment algorithm

8. Guidelines

8.1.1. Prurigo Nodularis Guidelines: The United States (2022)

8.1.2. Prurigo Nodularis IFSI Guidelines: Europe (2020)

8.1.3. Prurigo Nodularis Guidelines: Japan (2020)

9. Epidemiology and Patient Population of Prurigo Nodularis in the 7MM

9.1. Key Findings

9.2. Assumptions and Rationales

9.3. Total Diagnosed Prevalent Cases of Prurigo Nodularis in the 7MM

9.4. The United States

9.4.1. Total Diagnosed Prevalent Cases of Prurigo Nodularis in the United States

9.4.2. Gender-specific Diagnosed Prevalent Cases of Prurigo Nodularis in the United States

9.4.3. Age-specific Diagnosed Prevalent Cases of Prurigo Nodularis in the United States

9.4.4. Severity-specific Diagnosed Prevalent Cases of Prurigo Nodularis in the United States

9.5. EU4 and the UK

9.5.1. Total Diagnosed Prevalent Cases of Prurigo Nodularis in EU4 and the UK

9.5.2. Gender-specific Diagnosed Prevalent Cases of Prurigo Nodularis in EU4 and the UK

9.5.3. Age-specific Diagnosed Prevalent Cases of Prurigo Nodularis in EU4 and the UK

9.5.4. Severity-specific Diagnosed Prevalent Cases of Prurigo Nodularis in EU4 and the UK

9.6. Japan

9.6.1. Total Diagnosed Prevalent Cases of Prurigo Nodularis in Japan

9.6.2. Gender-specific Diagnosed Prevalent Cases of Prurigo Nodularis in Japan

9.6.3. Age-specific Diagnosed Prevalent Cases of Prurigo Nodularis in Japan

9.6.4. Severity-specific Diagnosed Prevalent Cases of Prurigo Nodularis in Japan

10. Patient Journey

11. Marketed Drugs

11.1. Key Cross Competition

11.2. NEMLUVIO/MITCHGA (nemolizumab-ilto): Galderma Laboratories/Maruho

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Clinical Development

11.2.4.1. Clinical Trial Information

11.2.5. Safety and Efficacy

11.3. DUPIXENT (dupilumab): Sanofi/Regeneron

11.3.1. Product Description

11.3.2. Regulatory Milestones

11.3.3. Other Developmental Activities

11.3.4. Clinical Development

11.3.4.1. Clinical Trial Information

11.3.5. Safety and Efficacy

12. Emerging Drugs

12.1. Key Cross Competition

12.2. Povorcitinib: Incyte

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.3.1. Clinical Trials Information

12.2.4. Safety and Efficacy

12.3. Ruxolitinib: Incyte

12.3.1. Product Description

12.3.2. Other Developmental Activities

12.3.3. Clinical Development

12.3.3.1. Clinical Trials Information

12.4. Rocatinlimab: Amgen/Kyowa Kirin

12.4.1. Product Description

12.4.2. Other Developmental Activities

12.4.3. Clinical Development

12.4.3.1. Clinical Trials Information

12.5. Barzolvolimab (CDX-0159): Celldex Therapeutics

12.5.1. Product Description

12.5.2. Other Developmental Activities

12.5.3. Clinical Development

12.5.3.1. Clinical Trial Information

12.5.4. Safety and Efficacy

12.6. Vixarelimab: Kiniksa Pharmaceuticals/Genentech

12.6.1. Product Description

12.6.2. Other Developmental Activities

12.6.3. Clinical Development

12.6.3.1. Clinical Trial Information

12.6.4. Safety and Efficacy

13. Prurigo Nodularis: 7MM Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. Key Market Forecast Assumptions

13.3.1. Cost Assumptions and Rebates

13.3.2. Pricing Trends

13.3.3. Analogue Assessment

13.3.4. Launch Year and Therapy Uptakes

13.4. Conjoint Analysis

13.5. Total Market Size of Prurigo Nodularis in the 7MM

13.6. Market Size of Prurigo Nodularis by Therapies in the 7MM

13.7. The United States Market Size

13.7.1. Total Market Size of Prurigo Nodularis in the United States

13.7.2. Market Size of Prurigo Nodularis by Therapies in United States

13.8. EU4 and the UK Market Size

13.8.1. Total Market Size of Prurigo Nodularis in EU4 and the UK

13.8.2. Market Size of Prurigo Nodularis by Therapies in EU4 and the UK

13.9. Japan Market Size

13.9.1. Total Market Size of Prurigo Nodularis in Japan

13.9.2. Market Size of Prurigo Nodularis by Therapies in Japan

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

17.1. United States

17.1.1. Centre for Medicare and Medicaid Services (CMS)

17.2. EU4 and the UK

17.2.1. Germany

17.2.2. France

17.2.3. Italy

17.2.4. Spain

17.2.5. United Kingdom

17.3. Japan

17.3.1. MHLW

17.4. Market Access and Reimbursement of Prurigo Nodularis

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DRA Capabilities

20. Disclaimer

21. About DRA